Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg. FC Tabs 60 X 5 mg
Rheumatoid arthritis:
5 mg twice/d, which should not be exceeded. No dose adjust. req. when used in comb. with methotrexate (MTX).
Psoriatic arthritis: 5 mg twice/d, which should not be exceeded.
No dose adjust. req. when used in comb. with MTX.
Ankylosing spondylitis: 5 mg twice/ d.
Ulcer. colitis –Induct. tmt.: 10 mg twice/d for 8 weeks.
For pts. who do not achieve adeq. therap. benefit by week 8, induct. dose can be extend. for an addit. 8 wks. (16 wks. total), followed by 5 mg twice/d for maint. Should be discont. in pts. who show no evid. of therap. benef. by wk. 16.
Ulcer. colitis –Mainten. tmt: 5 mg twice/d.
Juvenile idiopathic arthritis (JIA) dosing as per pt. weight:
betw 10 and 20 kg: 3. 2 mg X 2 dly
betw 20-40 kg: 4 mg X 2 dly
more than 40 kg: 5 mg X 2 dly. See full prescript. details
Rheumatoid arthritis: in combin. with methotrexate (MTX) for mod. to sev. active rheumatoid arthritis (RA) in adults who have respon. inadeq. to, or who are intol. to one or more dis.-modifying antirheumatic drugs (DMARDs). Can be given as monother. in case of intoler. to MTX or when MTX is inappropriate.Psoriatic arthritis: in combin. with MTX for active psoriatic arthritis (PsA) in adults who have had an inadeq. resp. or who have been intol. to a prior DMARD ther. Ulcerative colitis: for adults with moder. to sev. active ulcerative colitis (UC) who have had an inadeq. resp., lost resp, or were intol. to either convent. ther. or a bio. agent. Ankylosing spondylitis: for adults with active ankylosing spondylitis (AS) who have resp. inadeq. to convent. ther. Juvenile idiopathic arthritis (JIA): for active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in 2 years of age and older, who have resp. inadeq. to previous DMARDs. Can be given in combin. with MTX or as monother. in case of intoler. to MTX or where contin. tmt. with MTX is inapprop.
C/I: Hypersens. Active tuberc. (TB), serious infect. such as sepsis, or opportun. infect. • Severe hepatic impairm. • Pregn. and lactat.
Pazopanib 200 mg, 400 mg. Caps 200/400 mg X 30/60/90
800 mg once/d
Renal cell carcinoma (RCC): in adults for the first line tmt. of adv. RCC and for pts who have received prior cytokine ther. for adv. dis.
Soft tissue sarcoma (STS): for adult pts. with selective subtypes of adv. STS who have received prior chemother. for metast. dis. or who have progressed within 12 mo. after (neo) adjuvant ther.
C/I: Hypersens.
Kinase Inhibitor. momelotinib dihydrochloride 100 mg, 150 mg, 200 mg. FC Tab 30 X 100,150,200 mg
Daily dose: 200 mg. Not to be used with other JAK inhib. CBC and liver function to be tested before and during tmt.
Tmt. of intermediate or high-risk myelofibrosis (MF), including prim. MF or sec. MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
C/I: Hypersens. Pregn. and lactat
Enzyme Cofactor. Sapropterin 100 mg. Sol. Tabs. 30,120 X 100 mg
PKU (Phenylketonuria)
starting dose in adult and paed. pts. is 10 mg/kg BW once daily. Dose to be adjusted, between 5 and 20 mg/kg/d, to maintain adequate blood phenylalanine levels.
BH4 deficiency
starting dose in adult and paed. pts. is 2 to5 mg/kg BW total daily dose. Doses may be adjusted up to 20 mg/kg/d.
Tmt.of hyperphenylalaninaemia (HPA) in adults and paed. pts. of all ages with phenylketonuria (PKU) who have been shown to be responsive to such tmt.
Tmt.of hyperphenylalaninaemia (HPA) in adults and paed.pts. of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such tmt.
CI: Hypersens.
Corticosteroid, Vitamin D Analog. Calcipotriol (as monohydrate) 150 mcg/g, Betamethasone (as dipropionate) 0.5 mg/g. Gel: 30/60 g
To be applied to affected areas once/d. Tmt. period is 4 weeks for scalp areas and 8 weeks for “non-scalp” areas. If it is necessary to cont. or restart after this period, do so after medical review and under regular med. supervision.
When using calcipotriol cont. prod., the max. daily dose should not exceed 15 g. Body surface area treated with calcipotriol cont. prod. should not exceed 30%.
Tmt. of psoriasis of the scalp and tmt. of mild to moder. psoriasis vulgaris of other body areas in adults 18 years of age and older.
C/I: * Hypersens/ known disorders of calcium metabolism/
Erythrodermic, exfoliative and pustular psoriasis/ Due to the cont. of corticosteroid, contraindicated in:Viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infect., parasitic infect., skin manifest. in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers, wounds.
Androgen. Testosterone Undecanoate 250 mg/ml. Vial 1 X 4 ml sol. for IM inject.
One vial every 10 to 14 weeks is enough to maintain adeq. testosterone level without causing a build-up in blood.
Replacement ther. in prim. and sec. male hypogonadism
C/I: Women/Hypersens/ androgen-depend. carcinoma of the prostate or of the male mammary gland / past or present liver tumours .
התרופה האנטי-פסיכוטית JNJ-37822681, אנטגוניסט לדופמין D2 המתפרק במהירות, פועלת כפותחת תעלות עצביות מסוג Kv7- פוטנציאל לשימוש מחדש כטיפול באפילפסיה
ניסוי בקלדריבין בשנתיים שלאחר תחילת הטיפול בטרשת נפוצה
האם קיימים פערי מוצא במרשם תרופות לסרטן ערמונית גרורתי?
קוטר צוואר הרחם ומיפוי בלוטות לימפה בסרטן רירית הרחם
יעילות טיפול תחזוקתי קו ראשון בקרצינומה אורותליאלית מתקדמת
טיפול בסרטן ריאות מסוג ALK-חיובי: נתונים מהעולם האמיתי
תחלואה פסיכיאטרית לפני אבחון טרשת נפוצה ונכות עתידית
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Urinary Antispasmodic. Mirabegron 25 mg, 50 mg. PROLONG REL. TABS.: 30×25, 50 mg.
Adult. (include. elder. pts.) 50 mg once
daily with/without food.
Sympt. tmt. of urgency, incr. micturition
freq. and/or urgency incont. as may occur
in adult pts. with OAB syndr.
C/I: Hypersens.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
CGRP Antagonist, Monoclonal Antibody. Fremanezumab 225 mg. PREFILLED SYR (sol. for SC inj.): 1,3× 1.5ml. Tmt. is intended for pts. with at least 4 migraine days/month when initiat. tmt. with fremanezumab.
Two dosing options are available:
225 mg once mnthly. (mnthly. dosing) or 675 mg every three mnths. (quarterly dosing).
When switching dosing regimens, the first dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiat. tmt. with fremanezumab, concom. migraine prevent. tmt. may be continued if consid. necessary by the prescriber.
The tmt. benefit should be assessed within 3 mnths. after init. of tmt. Any further decision to continue tmt. should be taken on an individ. pt. basis. Evaluation of the need to continue tmt. is recomm. regularly thereafter.
Missed dose: If a fremanezumab inject. is missed on the planned date, dosing should resume as soon as possible on the indicated dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicat. for prophylaxis of migraine in adult. who have at least 4 migraine days per month.
C/I: Hypersens.
melatonin receptor agonists. Melatonin 1 mg, 5 mg. PR Tabs: 60 X 1 mg, 30 X 5mg. Recommend. Start. dose 2 mg. If inadeq. response observ., dose should be incr. to 5 mg, with a max. dose of 10 mg.
Drug should be taken once dly., 0.5-1 hr. before bedtime, with or after food.
Tmt. of insomnia in child. and adolesc. aged 2-18 with ASD and / or Smith-Magenis syndr., where sleep hygiene meas. have been insuff.
C/I: Hypersens.
Corticosteroid. Fluticasone Propionate 0.05%. METERED NASAL SPRAY: 120 doses. 2
sprays into ea. nostril 1 x dly. Child:
4-12 yrs: 1 spray into ea. nostril 1 x dly.
Under 4 yrs: Not recommended.
Proph. and tmt. seasonal allerg. rhinit.
incl. hayfever, perennial rhinit.
C/I: Hypersens. to compon.
Nicotine Receptor Partial Agonist. Varenicline (as tartrate) 0.5 mg, 1 mg. Health basket inclusion: Champix will be given to the treatment of smoking cessation parallel to supportive means.
TABS: 55 x 0.5 mg, 56 x 1 mg; starter pack: 11 x 0.5 mg + 14, 28 x 1 mg.
Days 1 – 3: 0.5 mg ×1/d.
Days 4– 7: 0.5 mg ×2/d.
Day 8 – end of tmt.: 1 mg ×2/d.
Pts. should be treated with Varenicline for 12 wks. For pts. who have successf. stopped smok. at the end of 12 wks., an addit. course of 12 wks. tmt. with Varenicline is recomm. to further incr. the likelihood of long-term abstinence.
Pts. with ren. impair. No dosage adjust. is necessary for pts. with mild- moder. renal impair. For pts. with sev. renal impair. (estimated CrCl <30 mL/min), the recomm. start. dose of Varenicline is 0.5 mg ×1/d. The dose may then be titrated as needed to a max. dose of 0.5 mg×2/d. For pts. with end-stage renal dis. underg. hemodialysis, a max. dose of 0.5 mg mg×/d may be admin. if toler.
Aid to smoking cessat. for adults over 18
yrs.
C/I: Hypersens., known skin react. to varenicline
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
